Feline Infectious Peritonitis: Welfare Implications

FIP was historically a fatal diagnosis for cats. New antiviral treatments have transformed outcomes, making this once-devastating disease now largely treatable.

Key Facts

FIP is caused by a mutated form of feline coronavirus and historically had nearly 100% fatality
The disease causes severe inflammation of body cavities or neurological tissue, causing progressive suffering
GS-441524, an antiviral drug, achieves remission in over 80% of FIP cases when treatment is completed
Treatment requires 84 days of daily injections or oral medication and costs $3,000-$10,000
The drug is now licensed in many countries following years of cats receiving gray-market treatment

Welfare Considerations

Feline infectious peritonitis represents a remarkable welfare transformation story. Before effective antivirals, an FIP diagnosis meant inevitable suffering and death within weeks to months. Owners faced the heartbreaking choice of euthanasia or watching their cat die progressively. The development of GS-441524 antiviral therapy fundamentally changed this reality — most cats treated respond well and go on to live normal lives. The welfare challenge now is access and cost: treatment remains expensive, and in many countries the drug is still not fully licensed, requiring import or gray market access. Ensuring that this life-saving treatment reaches all cats diagnosed with FIP — regardless of owner financial capacity — is the current welfare frontier.

What You Can Do

If your cat is diagnosed with FIP, consult an internal medicine specialist about antiviral treatment immediately
Support FIP Warriors and similar advocacy organizations working to improve drug access and reduce costs
Consider pet insurance that covers specialist treatment for cats, particularly younger cats at higher FIP risk
Advocate for full licensing of GS-441524 antiviral treatment in your country
Support research into FIP prevention through understanding coronavirus mutation triggers